BIBW 2992 (Afatinib)

DRUG3 trials

Sponsors

Boehringer Ingelheim, Universitätsklinikum Hamburg-Eppendorf, Medical University of South Carolina

Conditions

Lung CancerNeoplasmsRefractory Cancer

Phase 2

Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.

TerminatedNCT00748709

Boehringer IngelheimNeoplasms

Start: 2008-10-01Updated: 2025-02-11

BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer

TerminatedNCT01320280

Universitätsklinikum Hamburg-EppendorfRefractory Cancer

Start: 2011-05-31End: 2012-11-30Updated: 2022-07-01

A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)

WithdrawnNCT01480141

Medical University of South CarolinaLung Cancer

Start: 2012-01-31End: 2012-08-31Updated: 2013-03-26